multidrugresist
mdr
pathogen
worldwid
health
threat
clinic
neg
consequ
inadequ
recogn
treat
noncyst
fibrosi
bronchiectasi
chronic
structur
lung
condit
facilit
chronic
colon
microorgan
cours
frequent
exacerb
recurr
infect
mean
patient
receiv
numer
cours
broadspectrum
antibiot
make
like
acquir
mdr
pathogen
main
pathogen
involv
chronic
colon
acut
exacerb
haemophilu
influenza
streptococcu
pneumonia
pseudomona
aeruginosa
lesser
extent
enterobacteriacea
incid
spread
mdr
microorgan
among
patient
worrisom
antibiot
arsen
scarc
threaten
potenti
mdr
pathogen
respiratori
patient
includ
p
aeruginosa
extendedspectrum
betalactamas
esbl
enterobacteriacea
pathogen
difficult
treat
requir
differ
antibiot
regimen
usual
recommend
guidelin
knowledg
prospect
studi
aim
identifi
independ
risk
factor
mdr
pathogen
exacerb
hypothes
mdr
exacerb
depend
patient
characterist
includ
usual
treatment
prior
health
contact
knowledg
factor
may
use
reduc
inappropri
antibiot
treatment
aim
studi
investig
risk
factor
associ
isol
multidrug
resist
microorgan
bronchiectasi
exacerb
clinic
impact
outcom
data
collect
demograph
diagnosi
smoke
alcohol
abus
flu
vaccin
statu
comorbid
also
record
diabet
copd
asthma
heart
diseas
prior
tuberculosi
renal
liver
cerebrovascular
diseas
ageadjust
charlson
score
data
relat
prior
microorgan
isol
number
exacerb
previou
year
bronchiectasi
sever
score
bsi
face
also
record
chronic
concomit
medic
includ
bronchodil
corticosteroid
theophyllin
inhalednebul
antibiot
proton
pump
inhibitor
longterm
oxygen
therapi
mucolyt
drug
histori
prior
exacerb
hospit
previou
year
also
detail
definit
exacerb
accord
spanish
guidelin
follow
acut
chang
sputum
characterist
increas
volum
chang
viscos
purul
without
increas
dyspnea
rule
caus
along
requir
new
antibiot
treatment
prescrib
specif
clinic
unschedul
admiss
hospit
includ
also
exacerb
new
chest
xray
infiltr
diagnos
pneumonia
attend
physician
made
decis
admit
hospit
exacerb
episod
data
collect
chang
initi
antibiot
complic
invas
noninvas
mechan
ventil
mortal
length
hospit
stay
record
hospit
patient
new
exacerb
year
followup
inappropri
antibiot
treatment
consid
pathogen
suscept
prescrib
antibiot
respect
vitro
suscept
test
patient
follow
visit
special
clinic
day
day
year
discharg
microbiolog
diagnosi
perform
follow
test
sputum
patient
urin
antigen
test
pneumonia
l
pneumophila
two
blood
sampl
nasopharyng
swab
influenza
b
parainfluenza
syncyti
respiratori
viru
adenoviru
sputum
bronchoalveolar
lavag
process
gram
stain
cultur
bacteri
fungal
mycobacteri
pathogen
sputum
sampl
consid
accept
leukocyt
fewer
squamou
cell
per
lowpow
microscop
field
invas
sampl
obtain
request
attend
physician
microorgan
identif
consid
posit
previou
public
briefli
bacteri
identif
achiev
mean
malditof
ms
biomerieux
marci
l
etoil
franc
antimicrobi
suscept
test
kirbybau
disk
diffus
techniqu
mullerhinton
sheep
blood
agar
depend
microorgan
growth
requir
etest
inhous
pcr
use
assess
unexpect
resist
pattern
concept
multidrug
resist
pathogen
mdr
mdr
pathogen
classifi
accord
european
centr
diseas
prevent
control
p
aeruginosa
consid
mdr
non
suscept
least
agent
antimicrobi
categori
mrsa
defin
aureu
resist
oxacillin
correspond
minimum
inhibitori
concentr
mic
mcgml
enterobacteriacea
defin
esbl
present
resist
antibiot
includ
penicillin
cephalosporin
aztreonam
statist
analys
perform
use
spss
softwar
program
qualit
variabl
compar
use
test
quantit
variabl
analyz
use
anova
test
kruskalw
test
valu
p
consid
statist
signific
length
stay
dichotom
short
day
long
stay
face
bsi
dichotom
sever
point
respect
sever
logist
regress
analys
perform
predict
mdr
pathogen
depend
variabl
independ
variabl
includ
found
univari
analysi
p
variabl
highli
correl
exclud
analysi
subset
patient
nonmdr
pathogen
use
refer
group
second
logist
regress
analysi
also
perform
use
refer
group
patient
nonmdr
pathogen
patient
without
etiolog
diagnosi
hosmer
lemeshow
goodnessoffit
test
use
evalu
adequaci
model
area
receiveroper
characterist
roc
curv
also
calcul
recruit
patient
one
exacerb
microbi
isol
found
fig
characterist
patient
diagnosi
previou
microorgan
isol
number
exacerb
number
prior
antibiot
treatment
usual
concomit
medic
sever
score
describ
tabl
frequent
pathogen
found
exacerb
describ
tabl
mdr
pathogen
isol
exacerb
found
microorgan
repres
microorgan
isol
mdr
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
extendedspectrum
betalactamaseproduc
enterobacteriacea
proteu
mirabili
serratia
marcescen
bacteria
achromobact
xylosoxidan
stenotrophomona
maltophilia
brevundimona
diminuta
mdr
escherichia
coli
esbl
haemophilu
influenza
esbl
mdr
mycobacterium
abscessu
patient
requir
admiss
like
grow
mdr
organ
requir
admiss
vs
fig
antibiot
initi
prescrib
exacerb
chang
patient
occur
frequent
mdr
pathogen
without
reach
statist
signific
vs
tabl
depict
outcom
exacerb
regard
isol
mdr
pathogen
patient
without
isol
includ
characterist
patient
comorbid
condit
usual
treatment
score
regard
presenc
absenc
mdr
shown
tabl
exacerb
record
patient
hospit
admit
mdr
pathogen
frequent
encount
patient
chronic
condit
higher
face
bsi
score
differ
found
concern
usual
prior
treatment
patient
prior
hospit
show
significantli
frequent
incid
mdr
three
independ
predictor
mdr
exacerb
identifi
area
roc
curv
model
ci
tabl
second
model
use
refer
group
patient
nonmdr
pathogen
without
etiolog
diagnosi
risk
factor
remain
independ
associ
mdr
bacteria
presenc
mdr
exacerb
regard
number
recogn
risk
factor
found
shown
fig
risk
factor
identifi
patient
probabl
mdr
patient
probabl
increas
risk
factor
risk
factor
present
total
cohort
pathogen
identif
reli
mainli
convent
microbiolog
test
invas
respiratori
sampl
indic
requir
attend
physician
real
clinic
scenario
common
clinic
hospit
set
quantit
bacteriolog
measur
coloni
count
quantifi
sputum
due
number
patient
cohort
secondari
analysi
separ
specif
risk
factor
microorgan
undertaken
mild
episod
exacerb
treat
primari
care
evalu
specif
clinic
includ
first
studi
aim
identifi
risk
factor
mdr
exacerb
potenti
impact
clinic
decis
antibiot
choic
present
bt
guidelin
suggest
combin
therapi
rather
singledrug
antibiot
therapi
resist
strain
p
aeruginosa
isol
find
could
use
avoid
unnecessari
broadspectrum
antibiot
patient
without
mdr
risk
factor
find
identifi
three
independ
risk
factor
hospit
previou
year
chronic
renal
diseas
prior
multidrugresist
isol
identif
multidrugresist
pathogen
exacerb
inform
may
use
clinician
guid
initi
antibiot
therapi
exacerb
valid
differ
cohort
includ
distinct
phenotyp
larger
followup
period
perform
mdr
risk
predict
exacerb
new
field
requir
valid
clinic
decisionmak
select
initi
appropri
antibiot
safe
avoid
antimdr
coverag
